Clinical Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Special Laboratory of Mycology, Federal University of São Paulo, São Paulo, Brazil.
Mycoses. 2022 Apr;65(4):449-457. doi: 10.1111/myc.13433. Epub 2022 Feb 23.
COVID-19 patients on mechanical ventilation are at risk to develop invasive aspergillosis. To provide additional data regarding this intriguing entity, we conducted a retrospective study describing risk factors, radiology and prognosis of this emerging entity in a Brazilian referral centre.
This retrospective study included intubated (≥18 years) patients with COVID-19 admitted from April 2020 until July 2021 that had bronchoscopy to investigate pulmonary co-infections. COVID-19-associated aspergillosis (CAPA) was defined according to the 2020 European Confederation of Medical Mycology/International Society of Human and Animal Mycosis consensus criteria. The performance of tracheal aspirate (TA) cultures to diagnose CAPA were described, as well as the radiological findings, risk factors and outcomes.
Fourteen patients (14/87, 16%) had probable CAPA (0.9 cases per 100 ICU admissions). The sensitivity, specificity, positive predictive value and negative predictive value of TA for the diagnosis of CAPA were 85.7%, 73.1%, 46.2% and 95% respectively. Most of the radiological findings of CAPA were classified as typical of invasive pulmonary aspergillosis (64.3%). The overall mortality rate of probable CAPA was 71.4%. Age was the only independent risk factor for CAPA [p = .03; odds ratio (OR) 1.072]. CAPA patients under renal replacement therapy (RRT) may have a higher risk for a fatal outcome (p = .053, hazard ratio 8.047).
CAPA was a prevalent co-infection in our cohort of patients under mechanical ventilation. Older patients had a higher risk to develop CAPA, and a poor prognosis may be associated with RRT.
接受机械通气的 COVID-19 患者有发生侵袭性曲霉病的风险。为了提供有关这一有趣实体的更多数据,我们进行了一项回顾性研究,描述了巴西转诊中心中这一新兴实体的危险因素、影像学表现和预后。
这项回顾性研究纳入了 2020 年 4 月至 2021 年 7 月期间因 COVID-19 而接受机械通气(≥18 岁)并接受支气管镜检查以调查肺部合并感染的患者。根据 2020 年欧洲医学真菌学联合会/人类和动物真菌学国际协会共识标准,将 COVID-19 相关曲霉病(CAPA)定义为。描述了气管抽吸(TA)培养物用于诊断 CAPA 的表现,以及影像学表现、危险因素和结局。
14 名患者(14/87,16%)患有疑似 CAPA(每 100 例 ICU 入院 0.9 例)。TA 诊断 CAPA 的敏感性、特异性、阳性预测值和阴性预测值分别为 85.7%、73.1%、46.2%和 95%。CAPA 的大多数影像学表现均归类为侵袭性肺曲霉病的典型表现(64.3%)。疑似 CAPA 的总死亡率为 71.4%。年龄是 CAPA 的唯一独立危险因素[P=0.03;优势比(OR)1.072]。接受肾脏替代治疗(RRT)的 CAPA 患者可能有更高的致命结局风险(P=0.053,危险比 8.047)。
CAPA 是我们机械通气患者队列中普遍存在的合并感染。年龄较大的患者发生 CAPA 的风险更高,RRT 可能与不良预后相关。